Is China suppressing the spread of COVID variant NB.1.8.1? Virus is spreading - here's what Americans should do
Is China downplaying its COVID surge?
Live Events
Will current vaccines protect against Covid variant NB.1.8.1?
FAQs
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
A new COVID variant, NB.1.8.1, linked to a major surge in China, has been detected in the United States. The virus is believed to have arrived via international travelers, according to airport screenings and state reports.Experts are concerned, but the United States is currently experiencing low overall case numbers. It has been detected in several states, and while it is not yet widespread, it may become more contagious.Authorities say it's too early to panic, but they recommend taking precautions as new vaccines targeting related strains are being developed.Records submitted by the CDC's airport testing partner Ginkgo Bioworks show that cases associated with the NB.1.8.1 variant have been reported in arriving international travellers at airports in California, Washington state, Virginia, and the New York City area, as quoted in a report by CBS News.Information regarding the sequencing results, which were made public on the Global Initiative on Sharing All Influenza Data, or GISAID, virus database in recent weeks, indicates that travelers from a variety of nations, including China, Taiwan, Japan, South Korea, France, Thailand, the Netherlands, Spain, and Vietnam, are responsible for the cases.The variant, which is currently prevalent in China and is becoming more prevalent in other parts of Asia, has been the subject of intense scrutiny from experts.A CDC spokesperson said in a statement, "CDC is in regular contact with international partners and is aware of reported cases of COVID-19 NB.1.8.1 in China."The agency's variant estimates dashboard does not currently include enough reported U.S. sequences of NB.1.8.1.As the number of cases has increased, Hong Kong officials have begun to advise residents to wear masks in crowded areas and on public transit, despite their claims that there is no evidence that the variant, which is a descendant of the virus's XDV lineage, is more serious.Taiwanese health officials have also noted an increase in ER visits, serious illnesses, and fatalities. In reaction to the outbreak, local health officials say they are accumulating vaccines and antiviral medications.Americans are urged not to panic but remain vigilant and alert. With the number of cases remaining low nationally, health officials recommend reverting to simple precautions, particularly in crowded or confined areas. Wearing masks while using public transportation or during travel is an easy step to take to minimize risk.The need to update COVID-19 vaccines for the upcoming fall and winter seasons was discussed by outside vaccine advisers to the Food and Drug Administration.Last season's vaccines targeted a JN.1 descendant known as KP.2. According to preliminary data provided by Pfizer and Moderna, switching to a different JN.1 descendant known as LP.8.1 may increase protection against NB.1.8.1.Despite disagreements over specifics, the committee unanimously supported the recommendation that vaccines for the upcoming season target some form of JN.1 variant.While some advocated for the update to focus on the LP.8.1 descendant of JN.1 that Pfizer and Moderna have prototyped, others supported letting vaccine manufacturers continue using the vaccines from the previous season.Yes, it has been detected in travelers and reported in several states, including California, Ohio, and New York.Not yet, the variant isn't more severe, but it may spread more easily. Stay informed and consider vaccine options this autumn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
A shot of hope
New HIV medicine is powerful – but can everyone afford it? A new medicine called lenacapavir has just been approved in the US to help stop people from getting HIV, the virus that causes AIDS. That's big news! Even though fewer people are getting HIV today than in the 1990s, around 13 lakh (1.3 million) people still get infected every year around the world. Lenacapavir is special because you only need two shots a year – not a pill every day like older medicines. That's great for people who forget daily pills or feel embarrassed taking them. And it's almost 100% effective at stopping HIV in adults and teens. But there's a big problem: the cost. In the US, it sells for over ₹23 lakh a year! Even rich countries find that hard to afford. The company that makes it, Gilead, is working with more than 100 poorer countries to help them make cheaper versions. Still, many African countries where HIV is most common may struggle to get it to the people who need it most. Scientists have been trying to create a proper HIV vaccine for decades, but HIV keeps mutating – changing too fast for one shot to work. New mRNA vaccines (like the ones used for Covid) are being tested, but funding cuts in the US have slowed down this research. That's why lenacapavir gives us hope. But hope only works if everyone, everywhere, can afford it. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Time of India
2 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
Economic Times
3 hours ago
- Economic Times
Princess of Wales shares why she missed Royal Ascot, here's what she revealed
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The Princess of Wales , Catherine, has issued her first public statement after unexpectedly withdrawing from Royal Ascot . The 43-year-old was registered to ride in the second carriage alongside King Charles, Queen Camilla, and Prince William. However, she pulled out just 20 minutes before showtime, citing health concerns and the need to balance her recovery with public than comment on her absence from Ascot, Kate used the occasion to draw attention to Children's Hospice Week. As patron of East Anglia's Children's Hospices and Tŷ Hafan Children's Hospice in South Wales, she praised their said, 'No parent expects to hear that their child has a serious health condition… thousands are left heartbroken, fearful of the future and often desperately isolated.''Being able to access the support of one of the UK's 54 children's hospices means they don't have to face that future alone.'Kate returned to the public eye recently and attended Trooping the Colour and the Order of the Garter . She publicly announced her cancer remission in January after undergoing late withdrawal from Ascot came amid concerns about her overall energy levels. Palace insiders confirmed she was 'disappointed' but that fatigue played a key role. The abrupt cancellation caused temporary concern among aides before they clarified it was to protect her ongoing with the couple say she's learning to 'listen to her body' and carve out a sustainable balance between health and royal staff reportedly experienced a momentary 'panic' after her sudden absence. However, King Charles and Prince William supported her decision, prioritising health over royal reaction has been largely supportive. Commentators praised her thoughtful redirection of focus toward high-need charities during a time when public expectation had centred on her presence at Ascot.
